Systemic treatment of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease

doi:10.5306/wjco.v15.i11.1394

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (94)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

HTML

Tables (1-1)

Sum=84

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=7

Nov 24, 2024 (publication date) through Oct 20, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Nov 24, 2024; 15(11): 1394-1403
Published online Nov 24, 2024. doi: 10.5306/wjco.v15.i11.1394

Systemic treatment of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease

Karolina Rzeniewicz, Rohini Sharma

Karolina Rzeniewicz, Rohini Sharma, Department of Surgery and Cancer, Hammersmith Hospital, London W12 0NN, United Kingdom

Author contributions: Rzeniewicz K and Sharma R conceptualised the manuscript; Rzeniewicz K wrote the first draft; Sharma R critically reviewed and revised the manuscript. Both authors agreed on the submission journal, approved all versions of the manuscript, and agree to take accountability for its content.

Conflict-of-interest statement: Sharma R received consulting fees for SIRTEX, Esai; research funding (to institution) from Novartis, Astex Pharmaceuticals, Terumo and Boston Scientific. Rzeniewicz K has no conflict of interest to declare.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Rohini Sharma, Doctor, FRACP, MBBS, Professor, Senior Lecturer, Department of Surgery and Cancer, Hammersmith Hospital, 72 Du Cane Road, London W12 0NN, United Kingdom. r.sharma@imperial.ac.uk

Received: March 22, 2024
Revised: May 29, 2024
Accepted: August 5, 2024
Published online: November 24, 2024
Processing time: 205 Days and 8.8 Hours

Core Tip

Core Tip: Hepatocellular carcinoma (HCC) arising on a background of non-alcoholic fatty liver disease (NAFLD) is not well understood but patients tend to have poorer prognosis vs those with other HCC aetiologies. Currently all HCC patients are treated the same regardless of aetiology, and understanding of best treatment options for the NAFLD-HCC population is an urgent clinical need. This narrative review discusses NAFLD-HCC screening, pathophysiology, systemic treatment, and offers suggestions for future directions in this therapy area.